Natural history of multiple sclerosis includes phases of relapse, remission and insidious progression. New data show that sustained improvements in disease, defined by reductions in EDSS scores, occur independent of relapses almost half as frequently as disease worsening. This finding might facilitate research into the biological processes involved in disease improvement.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Tremlett, H. et al. Natural, innate improvements in multiple sclerosis disability. Mult. Scler. http://dx.doi.org/10.1177/1352458512439119.
[No authors listed] Double-masked trial of azathioprine in multiple sclerosis. British and Dutch Multiple Sclerosis Azathioprine Trial Group. Lancet 2, 179–183 (1988).
Jacobs, L. D. et al. Intramuscular interferon beta-1a for disease progression in relapsing–remitting multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann. Neurol. 39, 285–294 (1996).
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-beta-1a in MS (SPECTRIMS) Study Group. Randomized controlled trial of interferon-beta-1a in secondary progressive MS. Clinical results. Neurology 56, 1496–1504 (2001).
Liu, C. & Blumhardt, L. D. Disability outcome measures in therapeutic trials of relapsing–remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts. J. Neurol. Neurosurg. Psychiatry 68, 450–457 (2000).
Ebers, G. C., Heigenhauser, L., Saumer, M., Lederer, C. & Noseworthy, J. H. Disability as an outcome in MS clinical trials. Neurology 71, 624–631 (2008).
Coles, A. et al. Alemtuzumab versus interferon β-1a in early relapsing–remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurology 10, 338–348 (2011).
Albrecht, H. Day-to-day variability of maximum walking distance in MS patients can mislead to relevant changes in the Expanded Disability Status Scale (EDSS): average walking speed is a more constant parameter. Mult. Scler. 7, 105–109 (2001).
de Weerd, A. W. Variability of central conduction in the course of multiple sclerosis. Clin. Neurol. Neurosurg. 89, 9–15 (1987).
Guthri, T. C. & Nelson, D. A. Influence of temperature changes on multiple sclerosis: critical review of mechanisms and research potential. J. Neurol. Sci. 129, 1–8 (1995).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Andersen, O. Phases of disease improvement unrelated to relapses. Nat Rev Neurol 8, 596–598 (2012). https://doi.org/10.1038/nrneurol.2012.186
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2012.186
